Craig L. Slingluff
University of Virginia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
31
all conditions, ClinicalTrials.gov
NIH grants tied to them
15
NIH RePORTER
Trial papers
42
PubMed author-name match
Trials
Studies that name Craig L. Slingluff as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05839912 · Excision of Lymph Node Trial (EXCILYNT) (Mel69)Craig L Slingluff, Jr · recruiting · Melanoma
- Ph1/Ph2NCT04364230 · Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)Craig L Slingluff, Jr · completed · Melanoma, Ocular Melanoma, Uveal Melanoma · principal investigator
- Ph1/Ph2NCT03617328 · Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV MelanomaCraig L Slingluff, Jr · completed · Melanoma
- Ph1/Ph2NCT02643303 · A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer Research · completed · Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma
- Ph1/Ph2NCT02515227 · Safety Study of a Helper Peptide Vaccine Plus PembrolizumabCraig L Slingluff, Jr · completed · Melanoma · study director
- Ph1/Ph2NCT02425306 · Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of MelanomaCraig L Slingluff, Jr · terminated · Melanoma · principal investigator
- Ph1/Ph2NCT02385669 · A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaCraig L Slingluff, Jr · terminated · Melanoma · study director
- Early Ph1NCT02382549 · A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibCraig L Slingluff, Jr · terminated · Melanoma · study director
- Ph1/Ph2NCT02126579 · Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR AgonistsCraig L Slingluff, Jr · completed · Melanoma, Metastatic Melanoma, Mucosal Melanoma
- Ph1NCT01846143 · Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced MalignanciesCraig L Slingluff, Jr · completed · Melanoma · study director
- Ph1NCT01810016 · NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic MelanomaLudwig Institute for Cancer Research · terminated · Unresectable or Metastatic Melanoma
- Ph1NCT01585350 · A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma PatientsCraig L Slingluff, Jr · completed · Melanoma
- N/ANCT01531608 · Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In MelanomaUniversity of Virginia · completed · Melanoma
- Early Ph1NCT01425749 · Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCICraig L Slingluff, Jr · completed · Melanoma
- Ph1NCT01264731 · Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of MelanomaUniversity of Virginia · completed · Melanoma
- Ph1NCT00977145 · Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With MelanomaCraig L Slingluff, Jr · terminated · Melanoma · principal investigator
- N/ANCT00937690 · Pilot Study of Infrared Imaging of Cutaneous MelanomaUniversity of Virginia · completed · Melanoma
- Ph2NCT00928902 · Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk MelanomaUniversity of Virginia · completed · Melanoma
- N/ANCT00912418 · Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk MelanomaCraig L Slingluff, Jr · completed · Melanoma
- N/ANCT00912730 · A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for MelanomaUniversity of Virginia · completed · Melanoma
- N/A
- Ph1NCT00705640 · Vaccine Therapy in Treating Patients With Advanced MelanomaCraig L Slingluff, Jr · completed · Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin) · principal investigator
- Ph2NCT00373217 · Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCraig L Slingluff, Jr · terminated · Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Ph1/Ph2NCT00118274 · Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV MelanomaCraig L Slingluff, Jr · completed · Melanoma (Skin) · principal investigator
- Ph1NCT00118313 · Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV MelanomaCraig L Slingluff, Jr · completed · Melanoma (Skin) · principal investigator
- Ph1NCT00003224 · Vaccine Therapy in Treating Patients With Metastatic MelanomaUniversity of Virginia · completed · Melanoma (Skin) · study chair
- Ph2NCT00089206 · Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryUniversity of Virginia · completed · Intraocular Melanoma, Melanoma (Skin) · study chair
- Ph1/Ph2NCT00089219 · Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV MelanomaUniversity of Virginia · completed · Intraocular Melanoma, Melanoma (Skin) · study chair
- Ph2NCT00089193 · Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaCraig L Slingluff, Jr · completed · Melanoma (Skin) · study chair
- Ph2NCT00003222 · Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV MelanomaUniversity of Virginia · completed · Melanoma (Skin) · study chair
- Ph2NCT00071981 · Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic MelanomaEastern Cooperative Oncology Group · completed · Melanoma (Skin) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Postdoctoral Training Grant for MDs in Surgical Oncology ResearchT32CA163177 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2011 to 2026 · $493,034 awarded in 2026Same name and institution; not confirmed by an ID
- CRX - ProjectP30CA044579 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 1995 to 2024 · $46,771 awarded in 2024Grant number is on one of their registry trials
- Antibodies to melanoma vaccine peptidesR03CA219715 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2017 to 2018 · $80,750 awarded in 2018Same name and institution; not confirmed by an ID
- MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIESR01CA178846 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2015 to 2017 · $394,792 awarded in 2017Grant number is on one of their registry trials
- MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIESU01CA178846 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2013 to 2014 · $389,386 awarded in 2014Same name and institution; not confirmed by an ID
- Melanoma vaccines using MHC-associated peptidesR01CA057653 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 1997 to 2012 · $328,868 awarded in 2012Grant number is on one of their registry trials
- INTRATUMORAL INTERFERON GAMMA DURING VACCINATION IN METASTATIC MELANOMAM01RR000847 · NCRR · UNIVERSITY OF VIRGINIA · fiscal years 1998 to 2010 · $18,711 awarded in 2010Same name and institution; not confirmed by an ID
- Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk MelanomaR01CA118386 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2006 to 2010 · $116,450 awarded in 2010Same name and institution; not confirmed by an ID
- MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLSR01CA104362 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2005 to 2009 · $396,912 awarded in 2009Same name and institution; not confirmed by an ID
- Targeted Molecular Therapeutics for Melanoma: CCI-779 and BevacizumabR21CA128367 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2007 to 2008 · $293,721 awarded in 2008Same name and institution; not confirmed by an ID
- MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSFR21CA103528 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2003 to 2004 · $338,200 awarded in 2004Same name and institution; not confirmed by an ID
- VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDESR21CA105777 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2003 to 2004 · $338,200 awarded in 2004Same name and institution; not confirmed by an ID
- AUTOLOGOUS MELANOMA CELL VACCINE WITH GMCSF AND IL2R21CA089937 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 2000 to 2001 · $191,359 awarded in 2001Same name and institution; not confirmed by an ID
- PEPTIDE BASED VACCINES FOR STAGE IV MELANOMAR01CA078519 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 1998 to 2000 · $168,667 awarded in 2000Same name and institution; not confirmed by an ID
- HLA-A2 ASSOCIATED PEPTIDE EPITOPES FOR CTL ON MELANOMAR29CA057653 · NCI · UNIVERSITY OF VIRGINIA · fiscal years 1992 to 1996 · $108,844 awarded in 1996Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT00071981
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:33 UTC. The ranking covers the 200 most relevant of 42 PubMed records, and a shared surname and initials can bring in a namesake. All 42 on PubMed
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.Lancet Oncol · 2016287 citationsRCR 8.0
- 252 citationsRCR 4.7
- Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.Clin Cancer Res · 2001182 citationsRCR 3.4
- Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.Clin Cancer Res · 2009142 citationsRCR 2.9
- Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.Clin Cancer Res · 2007137 citationsRCR 2.7
- 110 citationsRCR 2.1
- Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.J Clin Oncol · 201197 citationsRCR 2.0
- Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.J Clin Oncol · 200895 citationsRCR 2.0
- A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).Clin Cancer Res · 201392 citationsRCR 2.3
- A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.J Immunother · 200886 citationsRCR 1.8